Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etanercept biosimilar - Pfizer

Next Previous
Drug Profile

Etanercept biosimilar - Pfizer

Alternative Names: Lifmior

Latest Information Update: 17 Nov 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins; Skin disorder therapies
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ankylosing spondylitis; Juvenile rheumatoid arthritis; Non-radiographic axial spondyloarthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis

Most Recent Events

  • 15 Dec 2016 Committee for Medicinal Products for Human Use (CHMP) of EMA recommends approval of Etanercept biosimilar for Rheumatoid arthritis, Juvenile idiopathic arthritis, Psoriatic arthritis, Plaque psoriasis (In children, In adolescents and In adults), Ankylosing spondylitis and Non-radiographic axial spondyloarthritis in European Union
  • 14 Dec 2016 Preregistration for Rheumatoid arthritis, Plaque psoriasis (In children, In adolescents, adults), Non-radiographic axial spondyloarthritis, Ankylosing spondylitis, Psoraitic arthritis and Juvenile rheumatoid arthritis in European Union (SC) before December 2016

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top